EUCTR2013-004984-30-GB进行中（未招募）1 期
A Blinded Long-term Extension Study to Evaluate the Safety and Efficacy of Pioglitazone (AD-4833 Sustained Release 0.8 mg Daily) to Slow the Progression of Cognitive Decline in Subjects Who Have Completed the AD-4833/TOMM40_301 Study With Diagnosis of Mild Cognitive Impairment Due to Alzheimer Disease
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. The subject completed the pivotal AD-4833/TOMM40_301 study with an adjudicated diagnosis of MCI due to AD without ongoing serious adverse events from study AD-4833/TOMM40_301.
- •2. The subject must be living independently or in nonmedical residential care.
- •3. The subject has a project partner able to separately consent on his/her own behalf and take part in the study (with the intent to do so as long as the subject is enrolled), providing information on the cognitive, functional, and behavioral status of the subject (and self reported, if voluntarily agreed to) and assisting with observation of adverse events and monitoring of study medication, if needed. (Project partners participating in the pivotal AD-4833/TOMM40_301 study are encouraged to participate in this extension study in this capacity.)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 149
排除标准
- •1. The subject completed the pivotal AD-4833/TOMM40_301 study with a diagnosis of AD dementia.
- •2. The subject has a current diagnosis of significant psychiatric illness, per Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (including but not limited to major depressive disorder, anxiety disorders) and is in an acute phase/episode, or the subject has a current diagnosis or history of schizophrenia or bipolar disorder.
- •3. The subject has a glycosylated hemoglobin >8% at the extension study Baseline Visit or requires treatment with insulin, triple oral antidiabetic therapy, or a peroxisome proliferator-activated receptor-gamma agonist.
- •4. The subject has a clinically significant unstable illness, for example, hepatic impairment or renal insufficiency, or cardiovascular, pulmonary, gastrointestinal (including s/p gastric bypass), endocrine, neurological, rheumatologic, immunologic, infectious, skin and subcutaneous tissue disorders, or metabolic disturbance.
- •5. The subject is required to take excluded medications as specified in the Excluded Medications Section of the protocol.
- •6. The subject had any of the following values at the extension study Baseline Visit:
- •- A serum total bilirubin value >1.5× upper limit of normal (ULN).
- •- A serum alanine aminotransferase or aspartate aminotransferase value >2×ULN.
- •- Unexplained microscopic/macroscopic hematuria on one repeat examination within 2 weeks.
- •7. The subject has a disease or takes medication that, in the opinion of the investigator, could interfere with the assessments of safety, tolerability, or efficacy, or prevent the subject from adequately participating in the study or continue for the anticipated duration of the study.
- •8. The subject has any cancer that has been in remission for less than 2 years from the extension study Baseline Visit.
- •9. Subjects with basal cell or stage I squamous cell carcinoma of the skin will be eligible. Subjects with current diagnosis of bladder cancer are not eligible irrespective of the remission status.
- •10. The subject has a current diagnosis of macular edema or macular degeneration.
- •11. The subject has a history or current diagnosis of congestive heart failure, New York Heart Association class III-IV.
研究者
相似试验
进行中（未招募）
2 期
A 5-year study to test BI 655130 in patients with Generalized Pustular Psoriasis who took part in previous studies with BI 655130Generalized Pustular Psoriasis (GPP)JPRN-jRCT2041210087Taguchi Aya131
进行中（未招募）
1 期
A 5-year study to test BI 655130 in patients with GeneralizedPustular Psoriasis who took part in previous studies with BI655130Generalized Pustular PsoriasisMedDRA version: 21.0Level: LLTClassification code 10037159Term: Psoriasis pustularSystem Organ Class: 100000004858EUCTR2018-003080-56-ESBoehringer Ingelheim España S.A.150
进行中（未招募）
1 期
A 5-year study to test BI 655130 in patients with Generalized Pustular Psoriasis who took part in previous studies with BI 655130EUCTR2018-003080-56-FRBoehringer Ingelheim France101
进行中（未招募）
1 期
A 5-year study to test BI 655130 in patients with GeneralizedPustular Psoriasis who took part in previous studies with BI655130EUCTR2018-003080-56-BGBoehringer Ingelheim RCV GmbH & Co KG150
进行中（未招募）
1 期
ong-Term Safety and Efficacy Evaluation of amlitelimab in adult participants with moderate to severe atopic dermatitis.EUCTR2021-002344-73-DESanofi-aventis recherche & développement315